Healthcare · NSE: NATCOPHARM · BSE: 524816
Natco Pharma: how the business works
Natco Pharma develops complex generic medicines that partner companies sell in the US, and sells cancer medicines in India, earning ₹4,078 crore of revenue in FY26.
Follow Natco Pharma
Email me when Natco Pharma's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Natco Pharma Limited · Hyderabad, Telangana · Founded 1981
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹4,078 cr
- Profit to shareholders, FY26
- ₹1,419 cr
- Share of FY26 revenue from the US
- 58.4%
- Incorporated
- 1981
- Promoter holding, 23 Oct 2026
- 46.22%
The short version
Natco Pharma in 5 points
1 · What it sells
Natco Pharma develops complex generic medicines that partner companies sell in the US, sells cancer and other medicines in India, and makes drug ingredients and crop-protection products, with FY26 revenue from operations of ₹4,078 crore.
2 · Who pays it
In FY26, customers in the US paid 58.4% of Natco's revenue, India 16.9% and other countries 24.7%, and one customer that Natco does not name paid ₹1,687 crore of it.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Natco kept ₹32.1 as profit, helped by a one-time ₹115 crore tax credit and ₹46.6 crore of profit from Adcock Ingram, while its operating EBITDA, which leaves out other income, was 35.2% of revenue (Cityfort calculation).
4 · Where the operating profit comes from
Pharmaceuticals earned a segment result of ₹1,547 crore in FY26 while crop health lost ₹19.8 crore, and in Q2 FY27 Natco's ₹29.2 crore share of Adcock Ingram's profit was 14.4% of its ₹203 crore profit for shareholders.
5 · The one thing to watch
Natco's revenue from operations was ₹967 crore in Q2 FY27 (Jul–Sep 2026), against ₹1,363 crore in Q2 FY26, and its 31 Dec 2026 balance sheet will be the first after the ₹1,279 crore rights issue of Oct 2026.
Sources: From Natco Pharma's FY26 annual report, its FY26, Q1 FY27 and Q2 FY27 results filings, its FY26 results presentation and its Q1 FY27 earnings call · checked
Sources (7)
- Annual Report 2025-26 (FY26)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Investor presentation August 2026
- Earnings presentation Q4 FY26 and FY26
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY26 consolidated results (XBRL, Integrated Filing)
- Allotment of 17,058,082 rights equity shares
01Where the money goes · FY26
Where does ₹100 of Natco Pharma's money go?
Natco Pharma · FY26
Receipt for every ₹100
| Materials and goods bought | ₹15.6 |
|---|---|
| Employee costs | ₹15.5 |
| Other running costs | ₹28.6 |
| Depreciation and interest | ₹5.5 |
| Income tax | ₹2.7 |
| Kept as profit for shareholders | ₹32.1 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 results: each line ÷ total money in × 100. Money in = revenue ₹4,078 crore + other income ₹298 crore + share of Adcock Ingram's profit ₹46.6 crore = ₹4,423 crore. Tax is low because of a one-time ₹115 crore credit in Q4 FY26.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Natco Pharma do?
Partner drug companies, distributors and other buyers in India and more than 50 export countries, most of all the US, pay Natco Pharma for its medicines and drug ingredients; running costs, materials and staff take most of the money, and ₹32.1 of every ₹100 that came in was left as profit in FY26.
- One customer that Natco does not name gave 41.4% of FY26 revenue, down from 60.6% in FY25.
- Quarterly revenue fell from ₹1,363 crore in Q2 FY26 to ₹647 crore in Q3 FY26; management said on 14 Nov 2025 that the Dec 2025 quarter would be the first without substantial sales of generic Revlimid (lenalidomide).
03Who pays it
Who pays Natco Pharma?
Buyers in the US
58.4%
of revenue
Natco sells its complex US generics through partner companies, and its export revenue includes profit share and licence income from partners. Revenue from the US was ₹2,381 crore in FY26, against ₹3,149 crore in FY25.
Buyers in India
16.9%
of revenue
Buyers of Natco's medicines in India, reached through more than 1,000 distributors, and Indian buyers of its drug ingredients and crop products: ₹691 crore in FY26.
Buyers in other countries
24.7%
of revenue
Customers in more than 50 countries, including those of Natco's subsidiaries in Brazil (₹288 crore of revenue in FY26) and Canada: ₹1,006 crore in FY26.
- Buyers in the US58.4%
- Buyers in India16.9%
- Buyers in other countries24.7%
Customer concentration
One customer that Natco does not name gave ₹1,687 crore, or 41.4% of FY26 revenue, against ₹2,686 crore (60.6%) in FY25 and 45.7% in FY24. That customer owed Natco ₹20.5 crore on 31 Mar 2026, against ₹731 crore a year earlier. ICRA says a few molecules drive the US business, particularly generic Revlimid in FY2025 and H1 FY2026.
- Largest customer
- 41%
Sources (6)
04How it makes money
How does Natco Pharma make money?
A few complex US generics have driven much of Natco's profit, so when one fades, revenue and margins swing sharply.
Natco's EBITDA margin (Cityfort calculation, without other income) was 49.6% in FY25, when generic Revlimid sales were high, and 35.2% in FY26. From Q3 FY26 Natco's share of Adcock Ingram's profit adds to its profit, outside revenue and EBITDA.
EBITDA per ₹100 of revenue (Cityfort calculation)
₹49.6₹35.2
FY25 to FY26
- Natco develops generics that are hard to make and files patent challenges in the US: 28 Para IV filings and more than 20 first-to-file as of 30 Jun 2026.
- Partner companies share the litigation and sell the medicine; Natco earns from the sale and a share of the profit.
- EBITDA was 49.6% of revenue in FY25 (Cityfort calculation); ICRA links that year's margin partly to profit share from generic Revlimid.
- ICRA said on 28 Nov 2025 it expected revenue and margins to moderate as the Revlimid patent expired; management said on 14 Aug 2026 that lenalidomide revenue was negligible in Q1 FY27.
- Quarterly revenue was ₹1,363 crore in Q2 FY26 and ₹647 crore in Q3 FY26; EBITDA margin was 24.5% in Q3 FY26.
- Natco used its own cash and a ₹400 crore term loan for its first Adcock Ingram stake, ICRA says; its share of Adcock's profit was ₹84.3 crore in Q1 FY27.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Natco Pharma?
Pharmaceuticals
96.6%Medicines and drug ingredients in all markets. Segment result ₹1,547 crore in FY26 (segment results include other income, before interest).
Revenue ₹3,940 cr · Operating profit ₹1,547 cr
Agro Chemicals
3.4%Crop-protection products (Crop Health Sciences). Segment loss of ₹19.8 crore in FY26; FY25's ₹146 crore loss included a ₹50 crore write-down of plant and equipment.
Revenue ₹138 cr · Operating profit −₹19.8 cr
How the mix changed
- Pharmaceuticals
- Agro Chemicals
Revenue by segment, FY22 to FY26.
₹ crore
See the numbers
Sources (6)
06The numbers · Consolidated · ₹ crore
How has Natco Pharma done?
Revenue
₹4,078 crFY26
Revenue rose from ₹1,945 crore in FY22 to ₹4,430 crore in FY25, then fell to ₹4,078 crore in FY26; it was ₹1,363 crore in Q2 FY26 and between ₹647 crore and ₹739 crore in each of the next three quarters; management said on 14 Nov 2025 that the Dec 2025 quarter would be the first without substantial Revlimid sales.
₹ crore
See the numbers
Net profit
₹1,419 crFY26
Profit for shareholders fell from ₹1,885 crore in FY25 to ₹1,419 crore in FY26, which includes a one-time ₹115 crore tax credit in Q4 FY26 (₹153 crore of Q4 profit without it, Cityfort calculation); Q1 FY27 profit of ₹207 crore includes ₹84.3 crore from Natco's share of Adcock Ingram's profit.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹34.8FY26
EBITDA (Cityfort calculation, leaving out other income) was 49.6% of revenue in FY25 and 35.2% in FY26, and 25.4% in Q1 FY27; Natco's own EBITDA includes other income and was ₹1,734 crore in FY26, 39.6% of total income.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹1,377 crFY26
Free cash flow (cash from operations minus spending on plants and intangibles) was ₹1,377 crore in FY26, against ₹1,185 crore in FY25; separately, Natco paid ₹2,079 crore for its first Adcock Ingram stake in FY26.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (17)
- Q4 FY22 and FY22 consolidated results (XBRL)
- Annual Report 2021-22 (FY22; NSE zip)
- Annual Report 2022-23 (FY23; NSE zip)
- Q4 FY23 and FY23 consolidated results (XBRL)
- Q4 FY24 and FY24 consolidated results (XBRL)
- Annual Report 2023-24 (FY24)
- Q4 FY25 and FY25 consolidated results (XBRL, Integrated Filing)
- Annual Report 2024-25 (FY25)
- Annual Report 2025-26 (FY26)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Q2 FY25 consolidated results (XBRL)
- Q3 FY25 consolidated results (XBRL)
- Q1 FY26 consolidated results (XBRL, Integrated Filing)
- Q2 FY26 consolidated results (XBRL, Integrated Filing)
- Q3 FY26 consolidated results (XBRL, Integrated Filing)
- Q1 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
07Who runs it
Who runs Natco Pharma, and did they deliver?
V C Nannapaneni
Chairman and Managing Director
Promoter.
Rajeev Nannapaneni
Vice Chairman and Chief Executive Officer
Part of the promoter family.
Amit Parekh
Chief Financial Officer · since 2026
From 13 Feb 2026, after S V V N Appa Rao retired on 12 Feb 2026.
Ch. Venkat Ramesh
Company Secretary
What they said, and what happened
2 partly delivered · 1 delivered · 2 too early to tell
Said on 14 Nov 2025
Management said on 14 Nov 2025 that, for the next six months, it expected a run rate of "around Rs 750 to 800 crores of revenue" a quarter and profit of around ₹135–150 crore a quarter.
Partly deliveredWhat happened
Revenue from operations was ₹647 crore in Q3 FY26 and ₹739 crore in Q4 FY26 (total income ₹705 crore and ₹817 crore). Profit was ₹152 crore and ₹268 crore; Q4 includes a one-time ₹115 crore tax credit (₹153 crore without it, Cityfort calculation).
Said on 14 Nov 2025
On generic semaglutide in India, management said on 14 Nov 2025 that it was "hoping we will be in the first wave in around March, April".
DeliveredWhat happened
Natco announced on 20 Mar 2026 that it would launch semaglutide vials in India the next day, the day the patent expired.
Said on 12 Feb 2026
Management said on 12 Feb 2026 that it expected FY26 to come in at "about INR4,200 crores to INR4,300 crores".
Partly deliveredWhat happened
The statement did not say which revenue measure it meant. FY26 revenue from operations was ₹4,078 crore, below the range, and total revenue including other income ₹4,376 crore, above it.
Said on 29 May 2026
Management said on 29 May 2026 that it expected FY27 revenue of about ₹3,400–3,500 crore and profit of ₹700–750 crore, including Adcock's profit share; on 14 Aug 2026 it put FY27 gross sales at ₹3,300–3,400 crore and profit at about ₹750 crore.
Too early to tellWhat happened
Total revenue including other income was ₹794 crore in Q1 FY27 and ₹1,019 crore in Q2 FY27, ₹1,814 crore for H1 FY27 (Cityfort calculation). Profit for shareholders was ₹409 crore in H1 FY27. Full-year figures come with the Q4 FY27 results.
Said on 14 Aug 2026
On the agro demerger, management said on 14 Aug 2026: "probably instead of December, it could be about March".
Too early to tellWhat happened
The board approved the scheme on 24 Mar 2026 with an appointed date of 1 Oct 2026; it had not taken effect in the filings checked to 15 Nov 2026.
Sources (15)
- Annual Report 2025-26 (FY26)
- Shareholding pattern as of 23 Oct 2026 (after rights allotment)
- Appointment of Amit Parekh as CFO from 13 Feb 2026
- Q2 FY26 earnings call transcript (call 14 Nov 2025)
- Q3 FY26 consolidated results (XBRL, Integrated Filing)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Earnings presentation Q4 FY26 and FY26
- Launch of generic semaglutide multi-dose vials in India
- Q3 FY26 earnings call transcript (call 12 Feb 2026)
- Q4 FY26 earnings call transcript (call 29 May 2026)
- Q1 FY27 earnings call transcript (call 14 Aug 2026)
- Investor presentation August 2026
- Earnings presentation Q2 FY27
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
- Board approval of scheme to demerge the agrochemicals business into Natco Crop Health Sciences Ltd
08What could go wrong
What could go wrong for Natco Pharma?
- Concentration
One customer, a few products
One customer that Natco does not name gave 41.4% of FY26 revenue and 60.6% of FY25 revenue. ICRA says disruption in any key product can cause large swings in revenue and margins.
Watch The customer-concentration note in the FY27 annual report (41.4% in FY26).
- Demand
Revenue after lenalidomide
Revenue from operations was ₹1,329 crore in Q1 FY26 and ₹1,363 crore in Q2 FY26, then between ₹647 crore and ₹739 crore in each of the next three quarters. It was ₹967 crore in Q2 FY27. Management said on 14 Aug 2026 that lenalidomide revenue was negligible in Q1 FY27. Natco said the Q2 FY27 fall from a year earlier was largely due to lower lenalidomide revenue.
Watch Q3 FY27 revenue, against ₹967 crore in Q2 FY27 and ₹647 crore in Q3 FY26.
- Other
Profit leans on Adcock Ingram
Natco's ₹84.3 crore share of Adcock's profit was about 41% of Q1 FY27 profit for shareholders. Management said a strong flu season in South Africa lifted that quarter and that the exchange rate affects Adcock's figures. In Q2 FY27 the share was ₹29.2 crore, 14.4% of profit (Cityfort calculation). Adcock reported ₹80.5 crore of Q2 profit; Natco said its share is after a provisional purchase price adjustment.
Watch Share of associate profit each quarter at the 49% stake (₹29.2 crore in Q2 FY27, ₹84.3 crore in Q1 FY27).
- Governance
Promoter shares pledged
850,000 shares of Chairman V C Nannapaneni were pledged in the 23 Oct 2026 filing, 0.94% of the promoter holding, the first pledge in the filings since Dec 2023. If pledged shares are sold to repay a loan, the promoter stake falls. The filings checked do not give a reason.
Watch Pledged shares in the Dec 2026 shareholding filing (850,000 on 23 Oct 2026).
- Regulation
US FDA inspections
Plants that supply the US must pass US FDA inspections. The Visakhapatnam formulation plant got a Form 483 with 4 observations in Aug 2026; the Kothur plant was under a warning letter from FY2024 until Sep 2025, ICRA says.
Watch The FDA's classification of the Aug 2026 Visakhapatnam inspection.
- Legal
Patent fights
Natco's model depends on challenging patents, and ICRA says it monitors any adverse outcome of such litigation. In India, Roche's risdiplam suit against Natco goes to trial after the Supreme Court dismissed Roche's petition on interim relief in Oct 2025.
Watch Court rulings and settlements announced by Natco or its partners.
- Execution
Acquisitions with the new money
The rights issue sets aside ₹339 crore for acquisitions not yet identified and general purposes. Management said in Aug 2026 that it was looking at acquisition opportunities, after spending about ₹3,000 crore, mostly on Adcock.
Watch Any acquisition announced, and borrowings after repayment (₹1,027 crore on 30 Sep 2026, before the rights money came in).
- Pricing
Price competition
ICRA notes competition-led price pressure in Natco's Indian and US markets. Management called the Indian semaglutide market super competitive in May 2026.
Watch Domestic formulations revenue each quarter (₹146 crore in Q2 FY27, ₹136 crore in Q1 FY27).
Sources (20)
- Annual Report 2025-26 (FY26)
- Annual Report 2024-25 (FY25)
- ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges
- Q1 FY26 consolidated results (XBRL, Integrated Filing)
- Q2 FY26 consolidated results (XBRL, Integrated Filing)
- Q3 FY26 consolidated results (XBRL, Integrated Filing)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Q1 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY27 board outcome and press release (results, second interim dividend)
- Q1 FY27 earnings call transcript (call 14 Aug 2026)
- Q4 FY26 earnings call transcript (call 29 May 2026)
- Natco completes acquisition of additional 13.25% stake in Adcock Ingram
- Shareholding pattern as of 23 Oct 2026 (after rights allotment)
- Shareholding pattern 2023-12-31
- US FDA inspection, Visakhapatnam FDF unit: Form 483 with 4 observations
- Legal update: Supreme Court dismisses Roche petition in Risdiplam suit
- Letter of Offer, rights issue 2026 (filed with Fund Raising Committee outcome 28 Sep 2026)
- Investor presentation August 2026
- Earnings presentation Q2 FY27
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Cash and liquid investments exceeded borrowings by ₹1,423 crore on 31 Mar 2026 (Cityfort calculation), and ICRA reaffirmed its AA (Stable) rating on 28 Nov 2025.
- Free cash flow was ₹1,377 crore in FY26, against ₹1,185 crore in FY25 (Cityfort calculation).
- Natco's share of Adcock Ingram's profit was ₹84.3 crore in Q1 FY27 at a 35.75% stake, and the stake rose to 49% in Jul 2026.
- Domestic formulations brought in ₹136 crore in Q1 FY27, against ₹107 crore in Q1 FY26, by the company's business-line figures.
- The company deck lists 28 Para IV filings, 17 approved (tentatively or fully) and more than 20 first-to-file as of 30 Jun 2026.
What critics point to
- Revenue from operations was ₹735 crore in Q1 FY27, against ₹1,329 crore in Q1 FY26, and management said on 14 Aug 2026 that lenalidomide revenue was negligible in Q1 FY27.
- One customer that Natco does not name gave 41.4% of FY26 revenue and 60.6% of FY25 revenue.
- About 41% of Q1 FY27 profit for shareholders came from Adcock Ingram, and management said a strong flu season in South Africa lifted that quarter.
- The promoter holding fell from 49.39% to 46.22% after the Oct 2026 rights issue, and 850,000 promoter shares were pledged, the first pledge in the filings since Dec 2023.
- The Visakhapatnam formulation plant received a US FDA Form 483 with 4 observations in Aug 2026.
10What to watch next
What should you watch next at Natco Pharma?
Next event
Q3 FY27 results (expected)
12 Feb 2027
Expected, based on last year's date
Q3 FY27 results, expected about mid-Feb 2027
Natco has not announced the date; Q3 FY26 results came on 12 Feb 2026. The 31 Dec 2026 balance sheet will be the first after the ₹1,279 crore rights issue of Oct 2026.
Sales and profit against guidance
Management said on 14 Aug 2026 it expects FY27 gross sales of ₹3,300–3,400 crore and profit of about ₹750 crore; H1 FY27 total revenue was ₹1,814 crore and profit ₹409 crore.
Promoter pledge and holding
On 23 Oct 2026 promoters held 46.22% and 850,000 of their shares were pledged; the Dec 2026 shareholding filing will show any change.
11Key facts
Key facts about Natco Pharma
- What does Natco Pharma do?
- Natco Pharma Ltd is a Hyderabad drug maker, incorporated in 1981, that develops complex generic medicines for the US with partner companies, sells cancer and other medicines in India, and makes drug ingredients (APIs) and crop-protection products. Natco Pharma's FY26 revenue from operations was ₹4,078 crore.
- How does Natco Pharma make money?
- By Natco Pharma's own business-line figures for FY26, formulation exports (including profit share and licence income from partners and sales of overseas subsidiaries) brought in ₹3,235 crore, domestic formulations ₹441 crore, APIs ₹235 crore and crop health products ₹138 crore, out of total revenue of ₹4,376 crore including other income.
- Who are Natco Pharma's customers?
- In FY26, customers in the US gave Natco Pharma 58.4% of its revenue from operations, India 16.9% and other countries 24.7%. One customer that Natco Pharma does not name gave ₹1,687 crore, or 41.4% of FY26 revenue, against 60.6% of FY25 revenue.
- How big is Natco Pharma?
- Natco Pharma's FY26 revenue from operations was ₹4,078 crore and its profit for shareholders ₹1,419 crore, against ₹4,430 crore and ₹1,885 crore in FY25. In Q2 FY27 (July to September 2026) Natco Pharma's revenue from operations was ₹967 crore and profit for shareholders ₹203 crore.
- Who owns Natco Pharma?
- On 23 Oct 2026, after its rights issue, Natco Pharma's promoter group, which includes Chairman and Managing Director V C Nannapaneni, held 46.22% of the shares, foreign institutions 15.36%, Indian institutions 10.82% (mutual funds 7.01%) and other shareholders 27.60%.
- What is Natco Pharma's stake in Adcock Ingram?
- Natco Pharma owns 49% of Adcock Ingram, a South African medicine maker: it bought 35.75% in Nov 2025 and 13.25% more in Jul 2026. Natco Pharma's share of Adcock Ingram's profit was ₹84.3 crore in Q1 FY27 and ₹29.2 crore in Q2 FY27, 14.4% of its ₹203 crore Q2 FY27 profit for shareholders (Cityfort calculation).
- Why did Natco Pharma's revenue fall?
- Natco Pharma's revenue from operations fell to ₹4,078 crore in FY26 from ₹4,430 crore in FY25, and was ₹967 crore in Q2 FY27 against ₹1,363 crore in Q2 FY26. Natco Pharma said in its Q2 FY27 results release that the fall was largely due to lower revenue from lenalidomide, its generic version of the US cancer medicine Revlimid.
- What was Natco Pharma's 2026 rights issue?
- Natco Pharma allotted 17,058,082 new shares at ₹750 each to existing shareholders on 23 Oct 2026, raising ₹1,279 crore; its Letter of Offer sets aside ₹811 crore of the net proceeds to repay borrowings. Natco Pharma's share count rose from 179,109,870 to 196,167,952.
- What dividend does Natco Pharma pay?
- Natco Pharma paid interim dividends of ₹5.00 a share for FY26 and ₹6.00 a share for FY25, and for FY27 declared interim dividends of ₹1.50 a share on 14 Aug 2026 and ₹1.25 a share on 13 Nov 2026 (record date 19 Nov 2026).
Sources (16)
- Annual Report 2025-26 (FY26)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Investor presentation August 2026
- Earnings presentation Q4 FY26 and FY26
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
- Shareholding pattern as of 23 Oct 2026 (after rights allotment)
- Adcock Ingram completes delisting from JSE; Natco acquires 35.75% stake
- Natco completes acquisition of additional 13.25% stake in Adcock Ingram
- Q1 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY26 consolidated results (XBRL, Integrated Filing)
- Q2 FY27 board outcome and press release (results, second interim dividend)
- Board outcome: rights issue terms (price, ratio, record date)
- Allotment of 17,058,082 rights equity shares
- Letter of Offer, rights issue 2026 (filed with Fund Raising Committee outcome 28 Sep 2026)
- Annual Report 2024-25 (FY25)
- Q1 FY27 board outcome and press release (results, interim dividend, fund-raise approval)
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Customer concentration
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Natco Pharma sell?
Generic medicines for the US and other export markets
Formulation exports, including profit share and licence income from partners and sales of overseas subsidiaries, brought in ₹3,235 crore in FY26, 73.9% of total revenue. Natco aims at products that are hard to make and have few competitors, and shares patent litigation and selling with partner companies. Its biggest product was lenalidomide, a generic of the US cancer medicine Revlimid (multiple myeloma), launched in the US in 2022.
Branded medicines in India
Domestic formulations brought in ₹441 crore in FY26. Natco has about 900 sales staff, more than 1,000 distributors and more than 40 cancer brands, 10 of them with sales above ₹10 crore. In Mar 2026 it launched generic semaglutide, a type 2 diabetes injection, in multi-dose vials from ₹1,290 a month.
Drug ingredients (APIs)
Active pharmaceutical ingredients, the chemical that makes a medicine work, sold to other drug makers: ₹235 crore in FY26.
Crop Health Sciences
Crop-protection products for farmers: ₹138 crore of revenue in FY26, with a segment loss of ₹19.8 crore. The board approved on 24 Mar 2026 a plan to demerge this business into Natco Crop Health Sciences Ltd; it has not taken effect.
49% of Adcock Ingram
A South African medicine maker. Natco bought 35.75% for about ₹2,000 crore (completed Nov 2025) and 13.25% more for ZAR 1,814.7 million, about ₹1,069 crore (completed 14 Jul 2026). Natco does not count Adcock's sales as its revenue; it books its share of Adcock's profit.
What it does
- Does: Files patent challenges in the US (Para IV filings, which ask to sell a generic before the brand's patents run out): 28 such filings, 17 approved (tentatively or fully), and more than 20 first-to-file, as of 30 Jun 2026 (company deck)
- Does: Spent ₹409 crore on research and development in FY26, 11.4% of standalone revenue
- Does: Runs 5 formulation plants, 2 API plants and 2 crop-health units (FY26 annual report)
- Does: Launched the first generic risdiplam, a spinal muscular atrophy medicine, in India, after courts refused Roche an interim injunction
What it does not do
- Does not: Does not name its largest customer, which gave 41.4% of FY26 revenue
- Does not: Does not sell most of its complex US products alone: partner companies handle distribution and share the patent litigation
- Does not: Does not include Adcock Ingram's sales in its revenue: only its share of Adcock's profit
Sources (10)
- Earnings presentation Q4 FY26 and FY26
- Investor presentation August 2026
- ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges
- Launch of generic semaglutide multi-dose vials in India
- Annual Report 2025-26 (FY26)
- Board approval of scheme to demerge the agrochemicals business into Natco Crop Health Sciences Ltd
- Board approval to acquire 35.75% of Adcock Ingram Holdings
- Adcock Ingram completes delisting from JSE; Natco acquires 35.75% stake
- Board approval to raise Adcock Ingram stake from 35.75% to 49%
- Natco completes acquisition of additional 13.25% stake in Adcock Ingram
13How the money flows
13How the money flows · FY26
How does money flow through Natco Pharma?
Money in
- Revenue from operations₹4,078 cr
- Share of Adcock Ingram's profit (associate)₹46.6 cr
- Other income₹298 cr
The company
Natco Pharma
₹4,423 cr came in
Money out
- Materials and goods bought₹691 cr
- Employee costs₹687 cr
- Other running costs₹1,264 cr
- Depreciation and interest₹243 cr
- Income tax (after a one-time ₹115 crore credit)₹119 cr
- Net profit for Natco shareholders₹1,419 cr
- In FY26 Natco's medicines, ingredients and crop products brought in ₹4,078 crore of revenue.
- Other income added ₹298 crore, and Natco's share of Adcock Ingram's profit added ₹46.6 crore.
- Materials and goods bought took ₹691 crore, staff ₹687 crore and other running costs ₹1,264 crore.
- Depreciation took ₹207 crore and interest ₹36.7 crore; income tax was ₹119 crore after a one-time ₹115 crore credit.
- What was left for Natco's shareholders was ₹1,419 crore of profit.
14What it needs to run
14What it needs to run
What does Natco Pharma need to run?
Plants
5 formulation plants, 2 API plants and 2 crop-health units in India; the company says 2 of the API plants and 2 of the formulation plants are approved by the US FDA.
US FDA clearance
Plants that supply the US are inspected by the US FDA. The Visakhapatnam formulation plant got a Form 483 (a list of inspection observations) with 4 observations in Aug 2026; the Kothur and Manali inspections of 2025 ended as Voluntary Action Indicated.
Partners for the US
For complex US products Natco works with global partner companies that share the patent litigation and the approval process and sell the medicine.
Research
₹409 crore spent on research and development in FY26 (standalone), against ₹373 crore in FY25.
People
5,060 permanent employees on the rolls at the end of FY26 (board's report).
Money for deals
ICRA says the first Adcock stake (about ₹2,000 crore) was paid from Natco's own cash and a ₹400 crore term loan; the Oct 2026 rights issue raised ₹1,279 crore.
Sources (7)
- Annual Report 2025-26 (FY26)
- Investor presentation August 2026
- US FDA inspection, Visakhapatnam FDF unit: Form 483 with 4 observations
- US FDA EIR for Kothur: Voluntary Action Indicated
- US FDA EIR for Manali API unit: Voluntary Action Indicated
- ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges
- Allotment of 17,058,082 rights equity shares
15Where it sells
15Where it sells · FY26
Where does Natco Pharma sell?
- USA58.4%
- India16.9%
- Rest of the world24.7%
Sources (1)
16Where growth could come from
16Where growth could come from
Where could Natco Pharma's growth come from?
On the Q1 FY27 call (14 Aug 2026) management said it would stick to the guidance given earlier in the year: FY27 profit of about ₹750 crore and gross sales between ₹3,300 crore and ₹3,400 crore. On the Q4 FY26 call (29 May 2026) it had said about ₹3,400–3,500 crore of revenue and ₹700–750 crore of profit, including Adcock's profit share.
Adcock Ingram
Mixed₹29.2 crore profit share, Q2 FY27
Natco's share of Adcock's profit was ₹10.9 crore in Q3 FY26, ₹35.7 crore in Q4 FY26 and ₹84.3 crore in Q1 FY27, at a 35.75% stake. Management said a strong flu season in South Africa lifted Q1, and that the share is normally about ₹35–40 crore a quarter at a 35% holding. The stake rose to 49% on 14 Jul 2026. The Q2 FY27 share was ₹29.2 crore, after an adjustment Natco links to a provisional purchase price allocation (the accounting step that values what it bought).
Status: Mixed, partly on track.
Branded medicines in India
Working₹146 crore, Q2 FY27 (₹105 crore in Q2 FY26)
Domestic formulations by the company's business-line figures, up 38.2% from a year earlier. Management said on 14 Aug 2026 that it expects domestic sales to grow about 25% in volume in FY27.
Status: Working, on track against what the company said.
Semaglutide in India
NewAbout ₹4 crore a month (May 2026)
Generic semaglutide vials launched in Mar 2026. Management said on 29 May 2026 that semaglutide added about ₹4 crore a month to sales, and it hoped for ₹75–100 crore annualised; it called the market super competitive.
Status: New, recently announced.
Brazil
Working₹178 crore, Q1 FY27 (+180%)
Revenue of Natco's Brazil business, as given on the Q1 FY27 call; the Brazil subsidiary's FY26 revenue was ₹288 crore.
Status: Working, on track against what the company said.
New US launches
Early29 Para IV filings, 30 Sep 2026
Asked about carfilzomib (a generic of the cancer medicine Kyprolis) on 14 Aug 2026, management said it could not confirm the date but the launch was on track. The Q2 FY27 presentation counts 29 Para IV filings at 30 Sep 2026, up from 28 at 30 Jun 2026.
Status: Early, too early to judge.
Crop Health Sciences
Mixed₹61.0 crore revenue, Q2 FY27
Agro revenue rose from ₹60.6 crore in FY25 to ₹138 crore in FY26, and the segment loss narrowed from ₹146 crore to ₹19.8 crore. In Q2 FY27 the segment made a ₹0.1 crore profit, after a loss in each of the eight earlier quarters on file. The demerger approved in Mar 2026 is pending; management said on 14 Aug 2026 it could complete about March instead of December.
Status: Mixed, partly on track.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (13)
- Q1 FY27 earnings call transcript (call 14 Aug 2026)
- Q4 FY26 earnings call transcript (call 29 May 2026)
- Q3 FY26 consolidated results (XBRL, Integrated Filing)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Q1 FY27 consolidated results (XBRL, Integrated Filing)
- Natco completes acquisition of additional 13.25% stake in Adcock Ingram
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY27 board outcome and press release (results, second interim dividend)
- Earnings presentation Q2 FY27
- Launch of generic semaglutide multi-dose vials in India
- Annual Report 2025-26 (FY26)
- Earnings presentation Q1 FY27
- Board approval of scheme to demerge the agrochemicals business into Natco Crop Health Sciences Ltd
17Financial strength and debt
17Financial strength · 31 Mar 2026
How much debt does Natco Pharma have?
- Total debt₹706 cr
- Cash and investments₹2,129 cr
- Net cash (cash minus debt)₹1,423 cr
- Net worth (shareholders' money)₹9,221 cr
- Debt to equity
- 0.08×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings rose from ₹273 crore on 31 Mar 2025 to ₹706 crore on 31 Mar 2026, including a ₹400 crore term loan, and were ₹954 crore on 31 Aug 2026 (rights issue Letter of Offer). Lease liabilities (₹7.5 crore on 31 Mar 2026) are not included.
- The Oct 2026 rights issue raised ₹1,279 crore after these dates; the Letter of Offer sets aside ₹811 crore of the net proceeds to repay borrowings, ₹110 crore for research and ₹339 crore for acquisitions not yet identified and general purposes.
- Cash and liquid investments = cash, other bank balances and current investments; debt to equity = borrowings ÷ net worth (Cityfort calculations). Deposits with financial institutions held under other financial assets are not counted.
- Natco's investment in Adcock Ingram was carried at ₹2,276 crore on 31 Mar 2026, of total assets of ₹11,074 crore.
18Who owns it
18Who owns it · 23 Oct 2026 (after the rights issue)
Who owns Natco Pharma?
- Promoters (founders or parent company)46.2%, of which pledged 0.4%
- Foreign institutions (FII)15.4%
- Indian institutions (DII)10.8%
- Public and others27.6%
- Pledged: 0.9% of promoter shares (0.4% of all shares)0.4%
Promoter shares pledged
0.9% of promoter shares
A pledge means promoters gave shares as security for a loan. If the loan isn't repaid, the lender can sell them.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (13)
- Shareholding pattern 2023-12-31
- Shareholding pattern 2024-03-31
- Shareholding pattern 2024-06-30
- Shareholding pattern 2024-09-30
- Shareholding pattern 2024-12-31
- Shareholding pattern 2025-03-31
- Shareholding pattern 2025-06-30
- Shareholding pattern 2025-09-30
- Shareholding pattern 2025-12-31
- Shareholding pattern 2026-03-31
- Shareholding pattern 2026-06-30
- Shareholding pattern 2026-09-30
- Shareholding pattern as of 23 Oct 2026 (after rights allotment)
19What it does with profit
19What it does with profit
What does Natco Pharma do with its profit?
Dividend per share
₹5.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
Buyback · 8 Mar 2023
The board approved an open-market buyback of up to ₹210 crore at up to ₹700 a share, with promoters excluded. Natco spent ₹7.4 crore in FY23 and ₹254 crore in FY24 on buybacks, including costs and tax, and its share count fell to 179,109,870.
₹210 cr
Money raised · 23 Oct 2026
Rights issue: 17,058,082 new shares at ₹750 each (2 for every 21 held), allotted on 23 Oct 2026; the share count rose to 196,167,952.
₹1,279 cr
Sources (7)
- Annual Report 2022-23 (FY23; NSE zip)
- Annual Report 2023-24 (FY24)
- Annual Report 2024-25 (FY25)
- Annual Report 2025-26 (FY26)
- Board outcome: rights issue terms (price, ratio, record date)
- Allotment of 17,058,082 rights equity shares
- Letter of Offer, rights issue 2026 (filed with Fund Raising Committee outcome 28 Sep 2026)
20Governance signals
20Governance signals
What do Natco Pharma's governance filings show?
- Auditor
- B S R and Co
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- Related-party transactions were not extracted for this page. The promoter group, which includes Chairman V C Nannapaneni, held 46.22% on 23 Oct 2026; Adcock Ingram is an associate (49% owned).
- Credit rating
- ICRA [ICRA]AA (long term) reaffirmed; [ICRA]A1+ (short term) (outlook Stable), 28 Nov 2025
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
pledge · 23 Oct 2026
First promoter pledge in the filings since Dec 2023
The 23 Oct 2026 shareholding filing shows 850,000 shares of V C Nannapaneni pledged: 0.94% of the promoter group's holding and 0.43% of all shares. The 12 quarter-end filings from Dec 2023 to Sep 2026 showed no pledge. The filings checked for this page do not give a reason.
other · 23 Oct 2026
Promoter holding diluted in the rights issue
The promoter holding fell from 49.39% on 30 Sep 2026 to 46.22% on 23 Oct 2026. Promoter shares rose from 88,465,126 to 90,676,902 (23 Oct 2026 filing), fewer than their full 2-for-21 entitlement. The Letter of Offer said promoters intended to subscribe in full or in part and might renounce.
regulatory · 14 May 2026
NPPA demand notice
On 12 May 2026 the National Pharmaceutical Pricing Authority issued a demand notice under the Drugs Price Control Order, 2013, directing Natco to deposit ₹4.92 crore (overcharge amount, penalty and interest). The notice alleges overcharging for 2 drugs from Apr 2023 to Nov 2023. Natco said there was no material impact.
regulatory · 21 Aug 2026
US FDA inspections
The US FDA issued a Form 483 with 4 observations at the Visakhapatnam formulation plant after an inspection from 17 to 21 Aug 2026; Natco said it believes they are procedural. ICRA says a warning letter at the Kothur plant, received in FY2024, was lifted in Sep 2025. Inspections at Kothur (Jun 2025, 7 observations), Mekaguda (Jun 2025, 1) and Manali (Nov 2025, 7) ended as Voluntary Action Indicated.
other · 12 Feb 2026
Change of finance chief
Amit Parekh became Chief Financial Officer on 13 Feb 2026, after S V V N Appa Rao retired on 12 Feb 2026.
Sources (16)
- Annual Report 2025-26 (FY26)
- Annual Report 2024-25 (FY25)
- Shareholding pattern as of 23 Oct 2026 (after rights allotment)
- Natco completes acquisition of additional 13.25% stake in Adcock Ingram
- ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges
- Shareholding pattern 2026-09-30
- Shareholding pattern 2023-12-31
- Letter of Offer, rights issue 2026 (filed with Fund Raising Committee outcome 28 Sep 2026)
- NPPA demand notice (Rs 4.92 crore, alleged overcharging, Apr-Nov 2023)
- US FDA inspection, Visakhapatnam FDF unit: Form 483 with 4 observations
- US FDA inspection, Kothur pharma division: Form 483 with 7 observations
- US FDA EIR for Kothur: Voluntary Action Indicated
- US FDA EIR for Mekaguda API unit (1 observation, VAI)
- US FDA inspection, Manali (Chennai) API unit: Form 483 with 7 observations
- US FDA EIR for Manali API unit: Voluntary Action Indicated
- Appointment of Amit Parekh as CFO from 13 Feb 2026
21What the market paid
21What the market paid · price as of 11 Nov 2026
What did the market pay for Natco Pharma on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹808.95, the NSE closing price, from before the Q2 FY27 results of 13 Nov 2026. Market value = price × 196,167,952 shares after the rights issue (23 Oct 2026) = ₹15,869 crore (Cityfort calculation). P/E (price ÷ earnings per share) = ₹808.95 ÷ ₹46.26, the earnings per share of the last four quarters (Q3 FY26 to Q2 FY27, on the share count before the rights issue) = 17.5 (Cityfort calculation). P/B = market value ÷ net worth on 30 Sep 2026 (₹9,765 crore, before the ₹1,279 crore rights issue) = 1.6. Dividend yield = FY26 dividend of ₹5.00 ÷ price = 0.62%.
- Share price
- ₹808.95
- Market value (market cap)
- ₹15,869 cr
- P/E
- 17.5×
- P/B
- 1.6×
Source: NSE CM bhavcopy 11 Nov 2026 (NATCOPHARM row); Shareholding pattern as of 23 Oct 2026 (after rights allotment); Q3 FY26 consolidated results (XBRL, Integrated Filing) and 5 more
Sources (8)
- NSE CM bhavcopy 11 Nov 2026 (NATCOPHARM row)
- Shareholding pattern as of 23 Oct 2026 (after rights allotment)
- Q3 FY26 consolidated results (XBRL, Integrated Filing)
- Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing)
- Q1 FY27 consolidated results (XBRL, Integrated Filing)
- Q2 FY27 consolidated results (XBRL, Integrated Filing)
- Annual Report 2025-26 (FY26)
- Allotment of 17,058,082 rights equity shares
22How it got here
22How it got here
How did Natco Pharma get here?
1981
Milestone
Incorporated in Hyderabad
Natco Pharma was incorporated in 1981 in Hyderabad.
1995
Milestone
Listed on the NSE
Natco's shares were listed on the National Stock Exchange on 27 Dec 1995.
2019
Business-model change
Crop Health Sciences starts
Natco launched its crop-protection division; the Visakhapatnam formulation plant began commercial production the same year.
2022
Business-model change
Generic Revlimid in the US
Natco and its partner launched generic lenalidomide (Revlimid) in the US in Mar 2022; Natco was first to file. Revenue grew from ₹1,945 crore in FY22 to ₹4,430 crore in FY25.
2025
Crisis
Lenalidomide sales fade
Management said on 14 Nov 2025 that the Dec 2025 quarter would be the first without substantial Revlimid sales; Q3 FY26 revenue was ₹647 crore, against ₹1,363 crore in Q2 FY26.
2025
Business-model change
35.75% of Adcock Ingram
Natco bought 35.75% of South Africa's Adcock Ingram for about ₹2,000 crore; the deal completed in Nov 2025, when Adcock delisted from the Johannesburg exchange.
2026
Milestone
Semaglutide, demerger plan, 49% of Adcock
Natco launched generic semaglutide in India in Mar 2026, its board approved the agro demerger on 24 Mar 2026, and its Adcock stake rose to 49% on 14 Jul 2026.
2026
Milestone
Rights issue
Natco raised ₹1,279 crore by issuing 17,058,082 shares at ₹750 to existing shareholders, allotted on 23 Oct 2026.
Sources (16)
- Annual Report 2025-26 (FY26)
- NSE equity list (NATCOPHARM: listed 27 Dec 1995, ISIN INE987B01026, face value Rs 2)
- Investor presentation August 2026
- ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges
- Q4 FY22 and FY22 consolidated results (XBRL)
- Q4 FY25 and FY25 consolidated results (XBRL, Integrated Filing)
- Q2 FY26 earnings call transcript (call 14 Nov 2025)
- Q3 FY26 consolidated results (XBRL, Integrated Filing)
- Q2 FY26 consolidated results (XBRL, Integrated Filing)
- Board approval to acquire 35.75% of Adcock Ingram Holdings
- Adcock Ingram completes delisting from JSE; Natco acquires 35.75% stake
- Launch of generic semaglutide multi-dose vials in India
- Board approval of scheme to demerge the agrochemicals business into Natco Crop Health Sciences Ltd
- Natco completes acquisition of additional 13.25% stake in Adcock Ingram
- Board outcome: rights issue terms (price, ratio, record date)
- Allotment of 17,058,082 rights equity shares
23What changed
23What changed · Q2 FY27
What changed in Q2 FY27?
Updated 16 Nov 2026
- Revenue from operations was ₹967 crore in Q2 FY27, down 29.0% from ₹1,363 crore in Q2 FY26. Natco said the fall was largely due to lower lenalidomide revenue.
- Profit for shareholders was ₹203 crore, against ₹518 crore in Q2 FY26 and ₹207 crore in Q1 FY27. EBITDA without other income was ₹258 crore, 26.7% of revenue (Cityfort calculation).
- Natco's share of Adcock Ingram's profit was ₹29.2 crore, against ₹84.3 crore in Q1 FY27. Natco said the Q2 figure is after an adjustment for a provisional purchase price allocation.
- Pharmaceuticals earned a segment result of ₹261 crore and crop health ₹0.1 crore, its first profit in the nine quarters on file. Domestic formulations revenue rose 38.2% to ₹146 crore.
- On 30 Sep 2026 borrowings were ₹1,027 crore, all due within a year, and cash and liquid investments ₹1,517 crore. The ₹1,279 crore from the rights issue came in Oct 2026.
- In H1 FY27 cash from operations was ₹165 crore, and Natco paid ₹1,060 crore for its second Adcock stake. The board declared a second interim dividend of ₹1.25 a share.
24Sources and changes
Where every number on this page comes from
Sources (61 documents)
- S1Annual Report 2025-26 (FY26) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Sep 2026
- S2Annual Report 2024-25 (FY25) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 29 Aug 2025
- S3Annual Report 2023-24 (FY24) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Sep 2024
- S4Annual Report 2022-23 (FY23; NSE zip) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Sep 2023
- S5Annual Report 2021-22 (FY22; NSE zip) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 2 Sep 2022
- S6Q1 FY27 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Aug 2026
- S7Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 29 May 2026
- S8Q3 FY26 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Feb 2026
- S9Q2 FY26 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Nov 2025
- S10Q1 FY26 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Aug 2025
- S11Q4 FY25 and FY25 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 28 May 2025
- S12Q3 FY25 consolidated results (XBRL) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Feb 2025
- S13Q2 FY25 consolidated results (XBRL) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Nov 2024
- S14Q4 FY24 and FY24 consolidated results (XBRL) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 May 2024
- S15Q4 FY23 and FY23 consolidated results (XBRL) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 29 May 2023
- S16Q4 FY22 and FY22 consolidated results (XBRL) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 31 May 2022
- S17Q1 FY27 board outcome and press release (results, interim dividend, fund-raise approval) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Aug 2026
- S18Earnings presentation Q1 FY27 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Aug 2026
- S19Investor presentation August 2026 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Aug 2026
- S20Earnings presentation Q4 FY26 and FY26 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 29 May 2026
- S21Q1 FY27 earnings call transcript (call 14 Aug 2026) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Aug 2026
- S22Q4 FY26 earnings call transcript (call 29 May 2026) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 4 Jun 2026
- S23Q3 FY26 earnings call transcript (call 12 Feb 2026) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Feb 2026
- S24Q2 FY26 earnings call transcript (call 14 Nov 2025) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 20 Nov 2025
- S25Shareholding pattern as of 23 Oct 2026 (after rights allotment) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 1 Nov 2026
- S26Shareholding pattern 2026-09-30 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 Oct 2026
- S27Shareholding pattern 2026-06-30 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Jul 2026
- S28Shareholding pattern 2026-03-31 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Apr 2026
- S29Shareholding pattern 2025-12-31 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Jan 2026
- S30Shareholding pattern 2025-09-30 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 9 Oct 2025
- S31Shareholding pattern 2025-06-30 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 15 Jul 2025
- S32Shareholding pattern 2025-03-31 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 Apr 2025
- S33Shareholding pattern 2024-12-31 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 8 Jan 2025
- S34Shareholding pattern 2024-09-30 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Oct 2024
- S35Shareholding pattern 2024-06-30 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 10 Jul 2024
- S36Shareholding pattern 2024-03-31 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Apr 2024
- S37Shareholding pattern 2023-12-31 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 8 Jan 2024
- S38ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges · ICRA Limited (via Natco filing on NSE) · Tier 2: rating agency or regulator · 29 Nov 2025
- S39Letter of Offer, rights issue 2026 (filed with Fund Raising Committee outcome 28 Sep 2026) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 28 Sep 2026
- S40Board outcome: rights issue terms (price, ratio, record date) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 25 Sep 2026
- S41Allotment of 17,058,082 rights equity shares · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Oct 2026
- S42Board approval to acquire 35.75% of Adcock Ingram Holdings · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Jul 2025
- S43Adcock Ingram completes delisting from JSE; Natco acquires 35.75% stake · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Nov 2025
- S44Board approval to raise Adcock Ingram stake from 35.75% to 49% · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 8 Jul 2026
- S45Natco completes acquisition of additional 13.25% stake in Adcock Ingram · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 Jul 2026
- S46Board approval of scheme to demerge the agrochemicals business into Natco Crop Health Sciences Ltd · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 24 Mar 2026
- S47Launch of generic semaglutide multi-dose vials in India · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 20 Mar 2026
- S48US FDA inspection, Kothur pharma division: Form 483 with 7 observations · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Jun 2025
- S49US FDA EIR for Kothur: Voluntary Action Indicated · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Sep 2025
- S50US FDA EIR for Mekaguda API unit (1 observation, VAI) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 24 Jul 2025
- S51US FDA inspection, Manali (Chennai) API unit: Form 483 with 7 observations · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 21 Nov 2025
- S52US FDA EIR for Manali API unit: Voluntary Action Indicated · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 Feb 2026
- S53US FDA inspection, Visakhapatnam FDF unit: Form 483 with 4 observations · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 21 Aug 2026
- S54Legal update: Supreme Court dismisses Roche petition in Risdiplam suit · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 17 Oct 2025
- S56NPPA demand notice (Rs 4.92 crore, alleged overcharging, Apr-Nov 2023) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 14 May 2026
- S57Appointment of Amit Parekh as CFO from 13 Feb 2026 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 Feb 2026
- S62NSE CM bhavcopy 11 Nov 2026 (NATCOPHARM row) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
- S63NSE equity list (NATCOPHARM: listed 27 Dec 1995, ISIN INE987B01026, face value Rs 2) · National Stock Exchange of India · Tier 1: company or exchange filing · 12 Nov 2026
- S65Q2 FY27 consolidated results (XBRL, Integrated Filing) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 Nov 2026
- S66Q2 FY27 board outcome and press release (results, second interim dividend) · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 Nov 2026
- S67Earnings presentation Q2 FY27 · Natco Pharma Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 Nov 2026
Changes to this page (v2 · 16 Nov 2026)
- v2 · 16 Nov 2026Q2 FY27 results (filed 13 Nov 2026) added: quarterly row, growth metrics, risk details, guidance outcome, P/E and P/B on the new figures, what changed, what to watch and key facts. (quarterly update, Q2 FY27)
- v1 · 12 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.